• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Genelux Corporation

    7/11/25 8:05:26 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNLX alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.__)

     

    Filed by the Registrant ☒
    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under § 240.14a-12

     

    GENELUX CORPORATION

    (Name of Registrant as Specified In Its Charter)

     

    Not Applicable

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required
    ☐ Fee paid previously with preliminary materials
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

     

    Get the next $GNLX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNLX

    DatePrice TargetRatingAnalyst
    10/29/2024$8.00Buy
    Guggenheim
    8/28/2024$10.00Buy
    ROTH MKM
    11/27/2023$35.00Buy
    H.C. Wainwright
    9/12/2023$40.00Buy
    Maxim Group
    2/15/2023$10.00Speculative Buy
    The Benchmark Company
    More analyst ratings

    $GNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Counsel & Secretary Groen Eric

    4 - GENELUX Corp (0001231457) (Issuer)

    7/2/25 4:16:07 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Groen Eric

    3 - GENELUX Corp (0001231457) (Issuer)

    7/2/25 4:14:58 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thomas John gifted 25,000 shares, decreasing direct ownership by 5% to 480,501 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/24/25 4:10:04 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    SEC Filings

    View All

    SEC Form S-8 filed by Genelux Corporation

    S-8 - GENELUX Corp (0001231457) (Filer)

    8/7/25 4:46:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Genelux Corporation

    10-Q - GENELUX Corp (0001231457) (Filer)

    8/7/25 4:07:33 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Genelux Corporation

    DEFA14A - GENELUX Corp (0001231457) (Filer)

    7/11/25 8:05:26 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

    WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

    7/7/25 7:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2025 and provided general business updates.   "The first quarter of 2025 has been highly productive and sets a strong foundation for the year ahead. We are well positioned to advance Olvi-Vec across multiple high-need cancer indications, with encouraging regulatory feedback from the FDA on our OnPrime Phase 3 registrational trial in resistant/refractory ovarian cancer, promising early lung cancer clinical data from our ongoing Phase 1b/2 study, and increasing patient enrollment in our U.S. Ph

    5/6/25 4:10:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Genelux with a new price target

    ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

    8/28/24 7:46:18 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Genelux with a new price target

    H.C. Wainwright initiated coverage of Genelux with a rating of Buy and set a new price target of $35.00

    11/27/23 7:16:52 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smither John W bought 6,250 shares, increasing direct ownership by 90% to 13,170 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:18 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNLX
    Leadership Updates

    Live Leadership Updates

    View All

    $GNLX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    $GNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

    WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025. "We are delighted to welcome Eric to the executive team," said Thomas Zindrick, President, CEO, and Chairman of the Board. "Eric brings a powerful blend of legal expertise, global business development savvy, and a strategic understanding of the biotechnology ecosystem. His proven ability to lead high-impact transactions, build trusted partnerships, and navigate complex regulatory

    7/7/25 7:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces New Chief Financial Officer

    WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt's financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux," said Thomas Zindrick, President, CEO and Chairman of the Board. "His unique combination of financial expertise and scientific background will be valuable as the company continues building towards the potential launch of Olvi-Vec." Mr. Pulisic is an ac

    2/3/25 6:45:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    10/25/24 9:45:20 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Genelux Corporation

    SC 13G/A - GENELUX Corp (0001231457) (Subject)

    10/22/24 4:12:19 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genelux Corporation

    SC 13G - GENELUX Corp (0001231457) (Subject)

    2/2/24 4:06:25 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care